Stanford Immunology Program, School of Medicine, Stanford University, 269 Campus drive, Stanford CA 94305-5174, United States.
Department of Chemistry, University of Nevada, Reno, 1664 North Virginia Street, NV 89557, United States.
Curr Top Med Chem. 2018;18(7):556-565. doi: 10.2174/1568026618666180518094322.
Protein-protein Interactions (PPIs) are particularly important for controlling both physiologic and pathologic biological processes but are difficult to target due to their large and/or shallow interaction surfaces unsuitable for small molecules. Linear peptides found in nature interact with some PPIs, and protein active regions can be used to design synthetic peptide compounds for inhibition of PPIs. However, linear peptides are limited therapeutically by poor metabolic and conformational stability, which can compromise their bioactivity and half-life. Cyclic peptidomimetics (modified peptides) can be used to overcome these challenges because they are more resistant to metabolic degradation and can be engineered to adopt desired conformations. Backbone cyclization is a strategy that we developed to improve drug-like properties of linear peptide leads without jeopardizing the integrity of functionally relevant side-chains. Here, we provide the first description of an entire approach for developing backbone cyclized peptide compounds, based upon two straightforward 'ABC' and 'DEF' processes. We present practical examples throughout our discussion of revealing active regions important for PPIs and identifying critical pharmacophores, as well as developing backbone cyclized peptide libraries and screening them using cycloscan. Finally, we review the impact of these advances and provide a summary of current ongoing work in the field.
蛋白质-蛋白质相互作用 (PPIs) 对控制生理和病理生物过程特别重要,但由于其较大和/或较浅的相互作用表面不适合小分子,因此难以成为靶点。天然存在的线性肽与一些 PPI 相互作用,并且可以使用蛋白质活性区域来设计用于抑制 PPI 的合成肽化合物。然而,线性肽在治疗上受到代谢和构象稳定性差的限制,这可能会影响它们的生物活性和半衰期。环肽类似物(修饰肽)可用于克服这些挑战,因为它们对代谢降解的抵抗力更强,并且可以设计成采用所需的构象。骨架环化是我们开发的一种策略,用于提高线性肽先导物的药物样特性,而不会危及功能相关侧链的完整性。在这里,我们提供了一种基于两个简单的“ABC”和“DEF”过程开发骨架环化肽化合物的完整方法的首次描述。在讨论揭示对 PPI 重要的活性区域和确定关键药效团以及开发骨架环化肽文库并使用 cycloscan 对其进行筛选时,我们提供了实际示例。最后,我们回顾了这些进展的影响,并总结了该领域当前正在进行的工作。